Hikma Pharmaceuticals's market cap is currently ―. The company's EPS TTM is p0.694; its P/E ratio is 26.28; and it has a dividend yield of 3.12%. Hikma Pharmaceuticals is scheduled to report earnings on August 8, 2024, and the estimated EPS forecast is p―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Jun 22	Dec 21	Jun 21	Dec 20
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	-	-	-	-	-
EBITDA	-	-	-	-	-
Net Income Common Stockholders	-	-	-	-	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 292.00M	$ 393.00M	$ 450.00M	$ 346.00M	$ 347.00M
Total Assets	$ 4.47B	$ 4.75B	$ 4.37B	$ 4.18B	$ 4.13B
Total Debt	$ 1.28B	$ 1.55B	$ 846.00M	$ 932.00M	$ 932.00M
Net Debt	$ 991.00M	$ 1.16B	$ 396.00M	$ 586.00M	$ 585.00M
Total Liabilities	$ 2.32B	$ 2.56B	$ 1.91B	$ 1.88B	$ 1.99B
Stockholders Equity	$ 2.13B	$ 2.18B	$ 2.45B	$ 2.29B	$ 2.13B
Cash Flow	-
Free Cash Flow	-	-	-	-	-
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in USD

Hikma Pharmaceuticals Earnings and Revenue History

Income Statement >

Hikma Pharmaceuticals Debt to Assets

Balance Sheet >

Hikma Pharmaceuticals Cash Flow

Cash Flow >

Hikma Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing